Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Haematopoietic Stem Cell Transplant Regimens


Published

Name Version Date
HSCT Allogeneic conditioning Myeloablative Haploidentical - Flu/Bu4 with PTCy [fludarabine and busulfan with post-transplant CYCLOPHOSPHamide]1.0.028/11/2024
HSCT Allogeneic conditioning Myeloablative Matched unrelated donor - Bu/Cy/ATG [busulfan, CYCLOPHOSPHamide and Thymoglobuline]1.0.028/11/2024
HSCT Allogeneic conditioning Myeloablative Matched unrelated donor - Flu/Bu4/ATG [fludarabine, busulfan, and Thymoglobuline]1.0.028/11/2024
HSCT Allogeneic conditioning Myeloablative Sibling - Bu/Cy [busulfan and CYCLOPHOSPHamide]1.0.028/11/2024
HSCT Allogeneic conditioning Myeloablative Sibling - Flu/Bu4 [fludarabine and busulfan]1.0.028/11/2024
HSCT Allogeneic conditioning Reduced intensity Matched unrelated donor - Flu/Bu2/ATG [fludarabine, busulfan, and Thymoglobuline]1.0.028/11/2024
HSCT Allogeneic conditioning Reduced intensity Sibling - Flu/Bu2 [fludarabine and busulfan]1.0.028/11/2024
HSCT Allogeneic conditioning Reduced intensity Sibling - Flu/Bu3 [fludarabine and busulfan]1.0.028/11/2024
HSCT Allogeneic conditioning Reduced intensity Sibling - Flu/Mel [fludarabine and melphalan]1.0.028/11/2024
HSCT Autologous conditioning - BEAM [carmustine, etoposide, cytarabine and melphalan] [lymphoma]1.0.028/11/2024
HSCT Autologous conditioning - carmustine and thiotepa [CNS lymphoma]1.0.028/11/2024
HSCT Autologous conditioning - CBV [CYCLOPHOSPHamide, carmustine and etoposide] [lymphoma]1.0.028/11/2024
HSCT Autologous conditioning - melphalan 1401.0.028/11/2024
HSCT Autologous conditioning - melphalan 2001.0.028/11/2024
HSCT Mobilisation - CYCLOPHOSPHamide and filgrastim1.0.028/11/2024
HSCT Mobilisation - filgrastim1.0.028/11/2024
HSCT Mobilisation - filgrastim and plerixafor1.0.028/11/2024